CTLA4Ig introduced by adenovirus vector locally to prolong the survival of xenogeneic skin grafts on rat burn wounds

Journal of Trauma - Injury, Infection and Critical Care

Volumn 59, Issue 5, 2005, Pages 1209-1215

  Luo, Gaoxing ^a   Wu, Jun ^a   Chen, Xiwei ^a   He, WeiFeng ^a   Yi, Shaoxuan ^a   Xie, Zhijie ^a   Zheng, Junshong ^a   Zhu, Jin ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Adenovirus vector; Burn; CTLA4Ig; Skin transplantation

Indexed keywords

ABATACEPT; ADENOVIRUS VECTOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DODECYL SULFATE SODIUM; HYBRID PROTEIN; RECOMBINANT ANTIGEN; RECOMBINANT CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BURN; BURN SCAR; CONCENTRATION RESPONSE; CONTROLLED STUDY; DERMIS; DOSE RESPONSE; FIBROBLAST CULTURE; GENETIC TRANSFECTION; GRAFT SURVIVAL; HUMAN; HUMAN TISSUE; IMMUNE FUNCTION TEST; IMMUNOHISTOCHEMISTRY; KERATINOCYTE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; RAT; SKIN FIBROBLAST; SKIN GRAFT; SKIN TRANSPLANTATION; SURVIVAL TIME; THERMAL INJURY; TRANSPLANTATION; VIRAL GENE DELIVERY SYSTEM; WESTERN BLOTTING; XENOGRAFT;

ADENOVIRIDAE; ANIMALS; BURNS; CELLS, CULTURED; GENETIC VECTORS; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOCONJUGATES; IMMUNOHISTOCHEMISTRY; IMMUNOLOGIC FACTORS; KERATINOCYTES; RATS; RATS, WISTAR; RECOMBINANT PROTEINS; SKIN TRANSPLANTATION; TRANSFECTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 30344453083     PISSN: 00225282     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ta.0000189002.59950.dc     Document Type: Article

References (34)

1. Lazarou SA, Barbul A, Wasserkrug HL, Efron A. The wound is a possible source of posttraumatic immunosuppression. Arch Surg. 1989;124:1429-1431.
2. Konigova R, Matouskova E, Broz L. Burn wound coverage and burn wound closure. Acta Chir Plast. 2000;42:64-68.
3. Fu X, Wang Z, Sheng Z. Advances in wound healing research in China: from antiquity to the present. Wound Repair Regen. 2001;9:2-10.
4. Caruso DM, Schuh WH, Al-Kasspooles MF, Chen MC, Schiller WR. Cultured composite autografts as coverage for an extensive body surface area burn: case report and review of the technology. Burns. 1999;25:771-779.
5. Zermani RG, Zarabini A, Trivisonno A. Micrografting in the treatment of severely burned patients. Burns. 1997;23:604-607.
6. Zhang ML, Chang ZD, Wang CY, Fang CH. Microskin grafting in the treatment of extensive burns: a preliminary report. J Trauma. 1988;28:804-807.
7. Zhang M, Zhou G, Zhang P. Microskin grafting in recent 15 years. Zhonghua Wai Ke Za Zhi. 2001;39:708-710.
8. Dooldeniya MD, Warrens AN. Xenotransplantation: where are we today? J R Soc Med. 2003;96:111-117.
9. Alexander JW. Mechanism of immunologic suppression in burn injury. J Trauma. 1990;30:S70-S75.
10. Konig W, Schluter B, Scheffer J, Koller M. Microbial pathogenicity and host defense in burned patients - the role of inflammatory mediators. Infection. 1992;20:S128-S134.
11. Jones ND, Turvey SE, Van Maurik A, et al. Differential susceptibility of heart, skin, and islet allografts to T cell-mediated rejection. J Immunol. 2001;166:2824-2830.
12. Guerder S, Flavell RA. Costimulation in tolerance and autoimmunity. Int Rev Immunol. 1995;13:135-146.
13. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annu Rev Immunol. 1996;14233-14258.
14. Najafian N, Sayegh MH. CTLA4-Ig: a novel immunosuppressive agent. Expert Opin Investig Drugs. 2000;9:2147-2157.
15. Baliga P, Chavin KD, Qin L, et al. CTLA4Ig prolongs allograft survival while suppressing cell-mediated immunity. Transplantation. 1994;58:1082-1090.
16. Miyake S. Makimura M, Kanegae Y, et al. Efficient generation of recombinant adenoviruses using adenovirus DNA-terminal protein complex and a cosmid bearing the full-length virus genome. Proc Natl Acad Sci USA. 1996;93:1320-1324.
17. Linsley PS, Brady W, Umes M, Grosmaire LS, Damle NK, Ledbetter JA. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med. 1991;174:561-569.
18. Yi SX, Wu J, Wang XH. Expression, purification and identification of CTLA4Ig fusion protein in COS-7. Di 3 Jun Yi Da Xue Xue Bao. 2000;22:523-526.
19. Linsley PS, Wallace PM, Johnson J, et al. Immunosuppression in vivo by a soluble form of the CTLA4 T cell activation molecule. Science. 1992;257:792-795.
20. Akita S, Ishihara H, Mohammad Abdur R, Fujii T. Leukemia inhibitory factor gene improves skin allograft survival in the mouse model. Transplantation. 2000; 70:1026-1031.
21. Nicolaidou E, Okada Y, Zuo XJ, et al. Prolongation of skin allograft survival is associated with reduced Th1 cytokine responses in the WKY->F344 rat model. Transplantation. 1999;68:1393-1401.
22. Ghahary A, Shen YJ, Scott PG, Tredget EE. Expression of mRNA for transforming growth factor-b1 is reduced in hypertrophic scar and normal dermal fibroblasts following serial passage in vitro. J Invest Dermatol. 1994;103:684-686.
23. Rheinwald JG, Green H. Serial cultivation of strains of human epidermal keratinocytes: the formation of keratinizing colonies from single cells. Cell. 1975;6:331-343.
24. Navsaria HA, Myers SR, Leigh IM, McKay IA. Culturing skin in vitro for wound therapy. Trends Biotechnol. 1995;13:91-100.
25. Weetall M, Digan ME, Hugo R, et al. T-cell depletion and graft survival induced by anti-human CD3 immunotoxins in human CD3epsilon transgenic mice. Transplantation. 2002;73:1658-66.
26. Schorlemmer HU, Kurrle R. Synergistic activity of malononitrilamides with cyclosporine to control and reverse xenograft rejection. Int J Tissue React. 1997;19:149-156.
27. Papalois BE, Wahoff DC, Sutherland DE, Clemmings S, Gores PF. T cell vaccination fails to prolong survival of skin allografts in mice. Transplantation. 1995;60:401-404.
28. Greenfield EA, Nguyen KA, Kuchroo VK. CD28/B7 costimulation: a review. Crit Rev Immunol. 1998;18:389-418.
29. Ellis JH, Burden MN, Vinogradov DV, et al. Interactions of CD80 and CD86 with CD28 and CTLA4. J Immunol. 1996;156:2700-2709.
30. Gimmi CD, Freeman GJ, Gribben JG, et al. Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc Natl Acad Sci USA. 1993;90:6586-6590.
31. Boussiotis VA, Lee BJ, Freeman GJ, et al. Induction of T cell clonal anergy results in resistance, whereas CD28-mediated costimulation primes for susceptibility to Fas- and Bax-mediated programmed cell death. J Immunol. 1997;159:3156-3167.
32. Lin H, Bolling SF, Linsley PS, et al. Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion. J Exp Med. 1993;178:1801-1806.
33. Bolling SF, Lin H, Turka LA. The time course of CTLA4Ig effect on cardiac allograft rejection. J Surg Res. 1996;63:320-323.
34. Noel PJ, Boise LH, Thompson CB. Regulation of T cell activation by CD28 and CTLA4. Adv Exp Med Biol. 1996;406:209-201.